Significance of Neuropilin-1 (CD 304) Expression in Paediatric B- Lineage Acute Lymphoblastic Leukemia (ALL)

  • Moizza Sahar Department of Haematology, University of Health Sciences
  • Fauzia Shafi Khan Children Hospital and Institute of Child Health,Ferozpur Road, Lahore
Keywords: NRP-1/CD304, Pediatric B-lineage ALL Patients, Minimal Residual Disease(MRD),, Flow Cytometry

Abstract

Background: To determine the prognostic
significance of NRP-1 (CD304) expression in
paediatric B-lineage Acute Lymphoblastic
Leukaemia (ALL) patients.
Methods: In this comparative study newly
diagnosed cases (aged 1-15 years) of B-ALL were
selected. Age and sex matched, 21 healthy controls
were also included in the study to assess the NRP-1
expression on peripheral blood lymphocytes. A
minimum 1ml of blood and bone marrow aspirate
samples were taken in EDTA vacutainer and
immunophenotyping was done on gated blast cells
using an extensive panel of antibodies including
myeloid markers (CD13, CD33 and cytoplasmic anti-
MPO) and lymphoid markers (CD34, CD2, CD3,
CD5, CD7, CD4, CD8, HLA DR, CD10, CD19, CD22;
cytoplasmic CD3, CD22, CD79a and nuclear anti-
TdT). The sample was considered NRP-1 positive if
20% or more of the gated blast cells expressed it .
Man-Witney U test and Kruskal Wallis test were
used for non-parametric data. The p value <0.05 was
considered significant.
Results: Out of 66 B-ALL patients, 53% were males.
There were 20 (30%) NRP-1 positive and 46 (70%)
NRP-1 negative patients. The prognosis of NRP-1
positive group was poor as compared to NRP-1
negative group with high blast percentage (80%) (p=
0.042), low morphological remission rate (21%)
(p=0.004) and low survival rate (29%) (p=0.009). The
mean survival days in dead patients was also less
(22.75 days).
Conclusion: NRP-1 over expression is associated
with disease progression and severity in paediatric
B-ALL patients.

Published
2019-05-02
How to Cite
1.
Sahar M, Shafi Khan F. Significance of Neuropilin-1 (CD 304) Expression in Paediatric B- Lineage Acute Lymphoblastic Leukemia (ALL). JRMC [Internet]. 2May2019 [cited 8Aug.2020];23(1):2-. Available from: http://journalrmc.com/index.php/JRMC/article/view/1075